Topic:

M&A

Latest Headlines

Latest Headlines

Celgene chief Bob Hugin isn't done betting on 'binary' biotech deals

By all accounts, the bidding war for Receptos was intense. But for Celgene CEO Bob Hugin and his go-to deals chief George Golumbeski, strategically this was exactly the right time to clinch a $7.2 billion buyout deal for the biotech and its lead drug ozanimod. And after they add this latest late-stage program to the pipeline, there are still more deals to be done.

UPDATED: Celgene shells out $7.2B for Receptos in a big bet on autoimmune disease

Celgene is trading $7.2 billion in cash for Receptos and its Phase III autoimmune treatment, building on some recent success in the field.

Playing catch-up on Big Biotech goal, Shire broadens M&A focus

Shire's $54 billion tie-up with AbbVie--and the subsequent cancellation of that deal--shook up employees and stalled CEO Flemming Ornskov's plans to transform the company into a biotech the likes of giants Gilead, Biogen and Celgene. It also took the Dublin drugmaker off course in one of its other endeavors: dealmaking.

UPDATED: Consumer groups urge FTC to take Mylan's side in Teva deal fight

Mylan is dead set against a buyout bid from generics rival Teva Pharmaceutical Industries. But some U.S. consumer groups are spooked by the very talk of a deal, and they're lobbying the Federal Trade Commission against it.

Valeant to buy contact lens maker Unilens for $28M

Tiny, OTC-traded Unilens Vision will be snapped up by acquisition-hungry Valeant Pharmaceticals for $28 million. The $12.75 deal share price is a huge uptick for the company, which started out the year with its shares hovering at about $7 per share.  

Endo, Mallinckrodt leverage different strengths in M&A hunt

Endo and Mallinckrodt have both been using M&A to help them head down the specialty pharma path. Both call Ireland home, helping them boast lower tax rates than many of their peers--and giving them a leg up in the dealmaking arena. And both generate the vast majority of their revenue in the U.S. But as Moody's points out, there are some important differences between them, too--and those will help determine their next M&A moves.

UPDATED: Depomed swallows poison pill to keep hostile Horizon at bay

Depomed was serious when it said it wasn't interested in Horizon Pharma's $29.25-per-share bid. Following the Irish pharma's move to take its hostile overture public last week, the company has put up its takeover defenses.

Medtronic to snap up startup that aims to prevent a major surgical error for $235M

Medtronic is paying $235 million to purchase RF Surgical Systems, which has a technology that's intended to make it easier to detect and prevent surgical items such as sponges, gauze or towels from being left behind in a patient.

Smith & Nephew strikes again, bolstering emerging markets with Russian trauma and orthopedics buy

Orthopedics player Smith & Nephew is rounding out its presence in emerging markets with the acquisition of the trauma and orthopedics business as well as a manufacturing company of the DeOst Group. The Russian company manufactures medical devices and has also served as Smith & Nephew's product distributor in the region since 2009.

Charles River bags new testing tech in $212M buyout

Charles River Laboratories has struck a deal to buy Celsis International for $212 million, nabbing its complementary bacterial detection systems for quality-control testing.